First metabolic profiling of Indian wild edible mushroom <i>Amanita hemibapha</i> reveals antimicrobial compounds that infers selective activity against gram-positive human pathogens

<i>Amanita hemibapha</i>, a wild edible mushroom from Western Ghats area of India, has been underexplored for its therapeutic properties. The present study uncovered selective inhibition of gram-positive human pathogens by the mushroom extracts and antibiofilm activity as the first report among <i>the Amanita</i> genus. The chloroform extract displayed the most effective inhibition against <i>Streptococcus pyogenes</i>, with both Minimum inhibitory concentration and Minimum bactericidal concentration registering at 6 mg/mL, and effective biofilm inhibition was recording at 4 mg/mL. Metabolic profiling of the chloroform fraction revealed an array of fatty acids, especially oleic acid and its derivatives like Oleoyl lysophosphatidylcholine and Azelaic acid, known to be selective for gram-positive pathogens. Sphingolipids like D-Sphingosine, Safingol, and threo-sphingosine profiled in the extract are effective gram-positive inhibitors. Metabolic profiling revealed the presence of medicinal and health-beneficial fatty acids/lipids in <i>A. hemibapha</i>. <i>Amanita hemibapha</i> chloroform extract selectively inhibited gram-positive pathogens and metabolic profiling revealed presence of compounds with selective inhibition property for gram-positive microbes.